| Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) CY Ho, SM Day, EA Ashley, M Michels, AC Pereira, D Jacoby, AL Cirino, ... Circulation 138 (14), 1387-1398, 2018 | 555 | 2018 |
| An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis O Agid, T Arenovich, G Sajeev, RB Zipursky, S Kapur, G Foussias, ... Journal of Clinical Psychiatry 72 (11), 1439, 2011 | 265 | 2011 |
| Methamphetamine use and schizophrenia: a population-based cohort study in California RC Callaghan, JK Cunningham, P Allebeck, T Arenovich, G Sajeev, ... American Journal of Psychiatry 169 (4), 389-396, 2012 | 156 | 2012 |
| Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders RC Callaghan, JK Cunningham, G Sajeev, SJ Kish Movement Disorders 25 (14), 2333-2339, 2010 | 153 | 2010 |
| Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy F Muntoni, J Domingos, AY Manzur, A Mayhew, M Guglieri, ... PLoS One 14 (9), e0221097, 2019 | 73 | 2019 |
| Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta‐analysis of disease progression rates in recent multicenter clinical trials CM McDonald, G Sajeev, Z Yao, E McDonnell, G Elfring, M Souza, ... Muscle & nerve 61 (1), 26-35, 2020 | 63 | 2020 |
| Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching O Agid, L Schulze, T Arenovich, G Sajeev, K McDonald, G Foussias, ... European Neuropsychopharmacology 23 (9), 1017-1022, 2013 | 62 | 2013 |
| Late-life cognitive activity and dementia: a systematic review and bias analysis G Sajeev, J Weuve, JW Jackson, TJ VanderWeele, DA Bennett, ... Epidemiology 27 (5), 732-742, 2016 | 60 | 2016 |
| The different trajectories of antipsychotic response: antipsychotics versus placebo TR Marques, T Arenovich, O Agid, G Sajeev, B Muthén, L Chen, BJ Kinon, ... Psychological medicine 41 (7), 1481-1488, 2011 | 57 | 2011 |
| Interpretation of epidemiologic studies very often lacked adequate consideration of confounding LG Hemkens, H Ewald, F Naudet, A Ladanie, JG Shaw, G Sajeev, ... Journal of clinical epidemiology 93, 94-102, 2018 | 56 | 2018 |
| Analysis of 34 candidate genes in bupropion and placebo remission AK Tiwari, CC Zai, G Sajeev, T Arenovich, DJ Müller, JL Kennedy International Journal of Neuropsychopharmacology 16 (4), 771-781, 2013 | 50 | 2013 |
| Predicting hospital length of stay for geriatric patients with mood disorders Z Ismail, T Arenovich, C Grieve, P Willett, G Sajeev, DC Mamo, ... The Canadian Journal of Psychiatry 57 (10), 627-634, 2012 | 35 | 2012 |
| Real-world outcomes of acute ischemic stroke treatment with intravenous recombinant tissue plasminogen activator KA Betts, D Hurley, J Song, G Sajeev, J Guo, EX Du, M Paschoalin, ... Journal of Stroke and Cerebrovascular Diseases 26 (9), 1996-2003, 2017 | 33 | 2017 |
| Suitability of external controls for drug evaluation in Duchenne muscular dystrophy N Goemans, J Signorovitch, G Sajeev, Z Yao, H Gordish-Dressman, ... Neurology 95 (10), e1381-e1391, 2020 | 30 | 2020 |
| Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections TM Welzel, M Yang, G Sajeev, YJ Chen, B Pinsky, Y Bao, EQ Wu, ... Advances in therapy 36, 2475-2486, 2019 | 30 | 2019 |
| Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional … N Goemans, B Wong, M Van den Hauwe, J Signorovitch, G Sajeev, D Cox, ... PloS one 15 (6), e0232870, 2020 | 28 | 2020 |
| Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy P Gorevic, J Franklin, J Chen, G Sajeev, JCH Wang, H Lin Expert Opinion on Pharmacotherapy 22 (1), 121-129, 2021 | 20 | 2021 |
| Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls F Muntoni, J Signorovitch, G Sajeev, N Goemans, B Wong, C Tian, ... Neuromuscular Disorders 32 (4), 271-283, 2022 | 15 | 2022 |
| DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials F Muntoni, J Signorovitch, G Sajeev, H Lane, M Jenkins, I Dieye, SJ Ward, ... Neurology 100 (15), e1540-e1554, 2023 | 10 | 2023 |
| Primary hyperoxaluria type 1 disease manifestations and healthcare utilization: a multi-country, online, chart review study X Wang, D Danese, T Brown, J Baldwin, G Sajeev, EE Cook, Y Wang, ... Frontiers in Medicine 8, 703305, 2021 | 8 | 2021 |
